Insulin Resistance in Type I Diabetes in Pediatric Care
Insulin Resistance in Type I Diabetes in Pediatric Care
Sponsors
Source
Nationwide Children's Hospital
Oversight Info
Has Dmc
No
Brief Summary
24 children (12 African-American, Hispanic, or American Indian, 12 Caucasian) previously
diagnosed with type 1 diabetes mellitus will participate in this pilot study to evaluate the
presence of hepatic and peripheral insulin resistance. The investigators will use this pilot
information to test the hypothesis that insulin resistance occurs in some children with type
1 DM, is secondary to underlying risk factors, and is responsible for increased insulin
needs. Methods will include a "step-up" hyperinsulinemic euglycemic clamp and infusion of the
stable isotope 6,6-[2H2]-glucose. Patient and parent interviews will be conducted to gather
information about nutritional intake, ethnicity, family history, and socioeconomic status.
The investigators will also measure inflammatory cytokines and free fatty acids to determine
whether they are associated with differences in insulin resistance among type 1 diabetes
mellitus patients.
Overall Status
Withdrawn
Start Date
2009-07-01
Completion Date
2010-05-01
Primary Completion Date
2010-05-01
Study Type
Observational
Primary Outcome
Measure |
Time Frame |
Insulin sensitivity |
Baseline |
Secondary Outcome
Measure |
Time Frame |
Hepatic glucose output |
Baseline |
Number Of Groups
1
Condition
Intervention
Intervention Type
Other
Intervention Name
Description
Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
Arm Group Label
Diagnostic
Eligibility
Study Pop
Endocrinology clinic patients
Sampling Method
Non-Probability Sample
Criteria
Inclusion Criteria:
- Previously diagnosed with type 1 diabetes
- ages 9 -11 tanner 1 or 16-23 tanner 4-5
Exclusion Criteria:
- None
Gender
All
Minimum Age
9 Years
Maximum Age
23 Years
Healthy Volunteers
No
Overall Official
Last Name |
Role |
Affiliation |
Dana S Hardin, MD |
Principal Investigator |
The Research Institute at Nationwide Children's Hospital, The Ohio State University |
Location
Facility |
Nationwide Children's Hospital Columbus Ohio 43205 United States |
Location Countries
Country
United States
Verification Date
2015-05-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Responsible Party
Name Title
Dana S. Hardin
Organization
The Research Institute at Nationwide Children's Hospital
Has Expanded Access
No
Condition Browse
Intervention Browse
Mesh Term
Insulin
Arm Group
Arm Group Label
Diagnostic
Description
Hyperinsulinemic euglycemic clamp
Firstreceived Results Date
N/A
Why Stopped
PI left institution
Firstreceived Results Disposition Date
N/A
Study Design Info
Observational Model
Case-Only
Time Perspective
Prospective
Study First Submitted
July 24, 2009
Study First Submitted Qc
July 24, 2009
Study First Posted
July 27, 2009
Last Update Submitted
May 14, 2015
Last Update Submitted Qc
May 14, 2015
Last Update Posted
May 15, 2015
ClinicalTrials.gov processed this data on December 13, 2019
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.